Lisdexamfetamine Pharmacokinetic Comparison Between Patients Who Underwent Roux-en-Y Gastric Bypass and Nonsurgical Controls

• Published in: Obesity surgery 2021-10, Vol.31 (10), p.4289-4294
• Main Authors: Steffen, Kristine J., Mohammad, Afroz S., Roerig, James L., Mitchell, James E., Nelson, Carrie, Orcutt, Molly, Zhang, Wenqiu, Erickson, Ann L., Elmquist, William F.
• Format: Article
• Language: English
• Subjects: Amphetamines; Body mass index; Gastrointestinal surgery; Medicine; Medicine & Public Health; Original Contributions; Pharmacokinetics; Plasma; Surgery
• ISSN: 0960-8923; 1708-0428
• DOI: 10.1007/s11695-020-04969-4

Introduction/Purpose The objective of this research was to characterize the impact of Roux-en-Y gastric bypass (RYGB) on the pharmacokinetic properties of the pro-drug lisdexamfetamine and its active metabolite, d-amphetamine. Materials and Methods A case-control design was used where patients who had undergone RYGB 9–24 months prior were matched on sex, age, and body mass index (BMI) to nonsurgical controls who had no history of weight loss surgery. Each participant received a single 50 mg dose of lisdexamfetamine, and plasma samples were collected over a 24-h period following dosing. Noncompartmental analyses were used to compare pharmacokinetic measures between groups. Results There were no significant differences between the RYGB ( n  = 10) and NSC groups ( n  = 10) on sex (70% female), age (40.9 ± 9.6 vs. 41.3 ± 8.9 years), BMI (30.3 ± 5.2 vs. 31 ± 5.9 kg/m 2 ), or ethnicity (100% vs. 80% White). The pharmacokinetic parameters between the RYGB and NCS groups were found to be equivalent for lisdexamfetamine and d-amphetamine, including maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax), and area under the plasma concentration–time curve (AUC (0–∞) ). Conclusion These data suggest that there is no need to routinely adjust lisdexamfetamine dosing following RYGB. However, given the potential for inter-individual differences, patients who undergo RYGB should be clinically monitored and individualized dosing strategies should be considered for concerns surrounding efficacy or toxicity.